Ariel Hurley Sells 1,834 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,834 shares of Blueprint Medicines stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $103.88, for a total value of $190,515.92. Following the transaction, the insider now owns 14,913 shares of the company’s stock, valued at approximately $1,549,162.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Blueprint Medicines Stock Up 2.2 %

BPMC stock opened at $108.55 on Wednesday. The stock has a fifty day moving average of $92.17 and a 200-day moving average of $81.81. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $110.93. The company has a market capitalization of $6.64 billion, a price-to-earnings ratio of -22.57 and a beta of 0.65. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.61 and a current ratio of 3.76.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 102.15% and a negative return on equity of 193.48%. The firm had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same quarter last year, the business earned ($2.65) earnings per share. The company’s quarterly revenue was up 85.5% on a year-over-year basis. As a group, equities research analysts predict that Blueprint Medicines Co. will post -5.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of BPMC. Vanguard Group Inc. lifted its position in shares of Blueprint Medicines by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after acquiring an additional 147,827 shares in the last quarter. Wellington Management Group LLP boosted its stake in Blueprint Medicines by 3.2% in the 3rd quarter. Wellington Management Group LLP now owns 5,080,521 shares of the biotechnology company’s stock worth $255,144,000 after purchasing an additional 156,807 shares during the period. Rock Springs Capital Management LP grew its holdings in Blueprint Medicines by 22.8% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,685,294 shares of the biotechnology company’s stock valued at $134,855,000 after buying an additional 498,622 shares in the last quarter. Polar Capital Holdings Plc increased its position in shares of Blueprint Medicines by 108.0% during the third quarter. Polar Capital Holdings Plc now owns 1,040,000 shares of the biotechnology company’s stock valued at $52,229,000 after buying an additional 540,000 shares during the period. Finally, Avidity Partners Management LP increased its position in shares of Blueprint Medicines by 81.1% during the third quarter. Avidity Partners Management LP now owns 751,600 shares of the biotechnology company’s stock valued at $37,745,000 after buying an additional 336,600 shares during the period.

Wall Street Analyst Weigh In

BPMC has been the topic of a number of recent research reports. Piper Sandler raised their target price on Blueprint Medicines from $78.00 to $104.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Citigroup raised their price objective on Blueprint Medicines from $65.00 to $76.00 and gave the company a “sell” rating in a research note on Friday, May 3rd. The Goldman Sachs Group upped their target price on shares of Blueprint Medicines from $121.00 to $168.00 and gave the stock a “buy” rating in a research note on Monday. Barclays raised their price target on shares of Blueprint Medicines from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, May 3rd. Finally, HC Wainwright upped their price objective on shares of Blueprint Medicines from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines currently has an average rating of “Hold” and a consensus price target of $100.31.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.